Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113242 | 0.82 | LMNA (1.00) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL7788141 | 0.82 | LMNA (0.72) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL3183961 | 0.81 | LMNA (0.60) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL3183953 | 0.81 | LMNA (0.60) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL15581474 | 0.81 | LMNA (0.70) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL4934431 | 0.81 | LMNA (0.70) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL4655041 | 0.80 | LMNA (0.58) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL12883033 | 0.79 | LMNA (0.68) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL8244217 | 0.78 | LMNA (0.66) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL20037188 | 0.78 | LMNA (0.66) | LMNAALDH1A1KDM4EPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2008099165-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | claimed |
| CN-110698481-B | Heteroaryl pyridone and aza-pyridone amide compounds | 豪夫迈·罗氏有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3089970-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015089075-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | LMNA 4755/4885ALDH1A1 3718/4885KDM4E 825/4885 |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | LMNA 2563/4885ALDH1A1 2649/4885KDM4E 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.